• <div id="y09gn"></div>
  • <li id="y09gn"></li>
    <dl id="y09gn"></dl>
    <div id="y09gn"><s id="y09gn"></s></div>
    来宝网Logo

    热门词:生物显微镜 水质分析仪 微波消解 荧光定量PCR 电化学工作站 生物安全柜

    现在位置首页>技术资料首页>行业动态>新品动态>Illumina公司推出一种全新的测序仪- HiSeq 2000

    Illumina公司推出一种全新的测序仪- HiSeq 2000

    Illumina2010年1月16日 16:28 点击:5132


    Illumina公司推出一种全新的测序仪- HiSeq 2000
    圣迭戈,2010年1月14日(商业新闻) - Illumina公司(纳斯达?#26031;?#31080;代码:ILMN)今天宣布AnalyzerIIe基因组测序系统,旨在提供到下一代测序价格?#31995;?#30340;切入点。价格为$ 250,000美元,新系统利用了Illumina的被广泛采用的基因组AnalyzerIIx已探明的排序由合成化学产生约2.00亿配对端对端架构读取和20 gigabases在发射(GB)的每运行数据。由于Illumina公司推出的进步,增加基因组AnalyzerIIx输出到95千兆,该基因组 AnalyzerIIe产量预计将达到40 Gb和30000.00万成对年?#33258;?#33267;运行读取。该系统的引人注目的价格点与易用性和测序技术的成熟,?#30001;?#29702;想职位下一代测序实验室?#34892;?#36259;较小。

    “随着基因组分析仪增加IIe收发,Illumina公司现在提供的测序业界最广泛的文书说,“杰伊弗拉特利,Illumina公司的总裁和首席执行官。”的基因组分析仪IIe收发 是一个特别重要的除了我们的产品,因为它将使一个实验室和有限的资本预算的多个机构能够以低成本增加下一代测序能力。“

    Illumina Introduces Genome AnalyzerIIe Sequencing System
    System Makes Next-Generation Sequencing Accessible to Broader Market
    SAN DIEGO, Jan 14, 2010 (BUSINESS WIRE) -- Illumina, Inc. (NASDAQ:ILMN) today announced the Genome AnalyzerIIe sequencing system, designed to provide a lower-priced entry point into next-generation sequencing. Priced at $250,000 USD, the new system leverages the architecture of Illumina's widely-adopted Genome AnalyzerIIx and its proven sequencing-by-synthesis chemistry to generate approximately 200 million paired-end reads and 20 gigabases (Gb) of data per run at launch. As Illumina introduces advances to increase the output of the Genome AnalyzerIIx to 95 Gb, the output of the Genome AnalyzerIIe is expected to reach 40 Gb and 300 million paired-end reads per run. The system's compelling price point coupled with its ease of use and proven sequencing technology ideally positions it for smaller laboratories interested in next-generation sequencing.

    "With the addition of the Genome AnalyzerIIe, Illumina now offers the broadest range of sequencing instruments in the industry," said Jay Flatley, president and CEO of Illumina. "The Genome AnalyzerIIe is a particularly important addition to our portfolio as it will allow a wide range of labs and institutions with limited capital budgets to affordably add next-generation sequencing capabilities."

    Illumina provides an extensive portfolio of sequencing instruments designed to meet a wide range of user and application requirements:

     

    • Genome AnalyzerIIe- For researchers with limited capital budgets, the Genome AnalyzerIIe provides an affordable entry point into next-generation sequencing. At launch, the Genome AnalyzerIIe provides 20 Gb of output and 200 million paired-end reads along with the industry's simplest workflow and system operation.
    • Genome AnalyzerIIx - The most widely adopted next-generation sequencing platform in the industry, the Genome AnalyzerIIx is ideally suited for researchers with medium to high output requirements. Currently generating in excess of 50 Gb of data per run, the Genome AnalyzerIIx is a proven and scalable platform offering application flexibility, ease of use, and low operating cost.
    • HiSeq 2000 - Redefining the trajectory of sequencing, HiSeq 2000 offers the best solution for applications demanding the highest throughput and lowest operating costs. With up to 200 Gb of output and two billion paired-end reads, HiSeq provides unprecedented sequencing output and user experience.
    • iScanSQ -- Capable of providing up to 20 Gb of output and 200 million paired-end reads, iScanSQ offers researchers the flexibility to access both sequencing and microarray processing on a single platform. It is expected to launch in Q2 2010.

     

    The Genome AnalyzerIIe is expected to begin shipping in Q1 2010. For more information on the Genome AnalyzerIIe and the full line of Illumina sequencing instruments, please visit our website at http://www.illumina.com/systems.

    About Illumina

    Illumina (http://www.illumina.com) is a leading developer, manufacturer, and marketer of next-generation life-science tools and integrated systems for the analysis of genetic variation and biological function. Using our proprietary technologies, we provide a comprehensive line of products and services that currently serve the sequencing, genotyping, and gene expression markets, and we expect to enter the market for molecular diagnostics. Our customers include leading genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations, and biotechnology companies. Our tools provide researchers around the world with the performance, throughput, cost effectiveness, and flexibility necessary to perform the billions of genetic tests needed to extract valuable medical information from advances in genomics and proteomics. We believe this information will enable researchers to correlate genetic variation and biological function, which will enhance drug discovery and clinical research, allow diseases to be detected earlier, and permit better choices of drugs for individual patients.

    Forward-Looking Statements

    This release contains forward-looking statements that involve risks and uncertainties. Examples of forward-looking statements include, but are not limited to, statements we make regarding the expected shipping dates for the Genome AnalyzerIIe and the iScanSQ. Important factors that could cause actual results to differ materially from those in any forward-looking statements include challenges inherent in new product development and manufacturing and the other factors that are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update any forward-looking statements after the date of this release.

    SOURCE: Illumina, Inc.

    Illumina, Inc.
    Investors
    Peter J. Fromen, 858-202-4507
    Sr. Director, Investor Relations
    [email protected]
    or
    Media:
    Wilson Grabill, 858-882-6822
    Senior Manager, Public Relations
    [email protected]


     

    (来源: Illumina )


    全年征稿 / 资讯合作

    联系邮箱:[email protected]

    版权与免责声明

    • 凡本网注明“来源:来宝网”的所有作品,版权均属于来宝网,转载请必须注明来宝网, http://www.67994619.com,违反者本网将追究相关法律责任。
    • 本网转载并注明自其它来源的作品,目的在于传递更多信息,并不代表本网赞同其观点或证实其内容的真实性,不承担此类作品侵权行为的直接责任及连带责任。其他媒体、网站或个人从本网转载时,必须保留本网注明的作品来源,并自负版权等法律责任。
    • 如涉及作品内容、版权?#20219;?#39064;,请在作品发表之日起一周内与本网联系,否则视为?#29260;?#30456;关权利。


    云南11选5技巧
  • <div id="y09gn"></div>
  • <li id="y09gn"></li>
    <dl id="y09gn"></dl>
    <div id="y09gn"><s id="y09gn"></s></div>
  • <div id="y09gn"></div>
  • <li id="y09gn"></li>
    <dl id="y09gn"></dl>
    <div id="y09gn"><s id="y09gn"></s></div>
    广西快乐十分走势图 青海福利快三开奖查询 黑龙江6+1 重庆幸运农场直播开奖视频 竟彩彩票 甘肃十一选五任四多少钱 浙江体彩20选5走势图超长版 广东时时彩有几种玩法 内蒙古快三形态走势图彩经网 香港百姓网三肖中特期期准 足球让分胜负 3d三十期开机号和试机号分析 湖南快乐十分走势图 极速赛车5码精准计划 幸运武林标志